Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Analyst Comments: United Thera, Genta, Visteon, Watsco, Autonation, National Semi, Saks, Lehman, Joy Global, Nuvelo, 3D Systems, Suntech Power, Dassault, Cell Therapeutics, Analog Devices, Energy Transfer, General Growth
Aug 20, 2008 04:03 PM
- FedEx, Financials, & Oil Prices
Jun 18, 2008 11:22 AM
- Uncle Ben Once Again
Apr 02, 2008 10:13 AM
- Analyst Comments: Cell Therapeutics, CastlePoint Holdings, Churchill Downs, Acusphere, Goldman Sachs, Lehman Brothers
Mar 18, 2008 10:49 AM
- Buy Cell Therapeutics
Jan 16, 2008 10:45 AM
- January Barometer
Jan 02, 2008 10:23 AM
- Pre-Market
Nov 09, 2007 10:46 AM
- Pre-Market - Thursday September 6th
Sep 06, 2007 10:27 AM
- Pre-Market - Thursday July 26th
Jul 26, 2007 05:52 PM
- Top Percentage Gainers and Losers
Jul 13, 2007 11:15 AM
- Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Date of April 2, 2009
Dec 01, 2008 07:06 AM
- FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Dec 01, 2008 01:30 AM
- Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
Dec 01, 2008 01:30 AM
- Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
Nov 28, 2008 01:30 AM
- Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
Nov 26, 2008 10:02 AM
- Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Nov 11, 2008 01:30 AM
- Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma
Nov 10, 2008 01:30 AM
- Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008
Nov 07, 2008 01:30 AM
- Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
Nov 06, 2008 01:30 AM
- Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
Nov 05, 2008 04:30 PM
- Form 4 BIANCO JAMES A For: Oct 22 (10K)
Oct 24, 2008 08:42 PM
- Form 4 BIANCO LOUIS A For: Oct 22 (10K)
Oct 24, 2008 08:26 PM
- Form 4 PHILIPS CRAIG For: Oct 22 (10K)
Oct 24, 2008 08:12 PM
- Form 4 SINGER JACK W For: Oct 22 (10K)
Oct 24, 2008 08:04 PM
- Form 4 Eramian Daniel G For: Oct 22 (10K)
Oct 24, 2008 07:51 PM
- Form 4 Telling Fred For: Oct 22 (10K)
Oct 24, 2008 07:38 PM
- Form 4 NUDELMAN PHILLIP M PHD For: Oct 22 (10K)
Oct 24, 2008 07:24 PM
- Form 4 MUNDINGER MARY ONEIL For: Oct 22 (10K)
Oct 24, 2008 07:14 PM
- Form 4 LOVE RICHARD L For: Oct 22 (10K)
Oct 24, 2008 07:03 PM
- Form 4 GREGORIAN VARTAN For: Oct 22 (10K)
Oct 24, 2008 06:30 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
CTIC
|
Compare to S&P
|
| YTD |
-99.15 %
|
-98.61 %
|
| 4 Weeks |
-48.39 %
|
-44.21 %
|
| 12 Weeks |
-91.58 %
|
-88.33 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 39.79 %
|
|
EPS Growth in Last Year: 74.04 %
|
|
Sales Growth in Last Quarter: -10.03 %
|
|
Sales Growth in Last Quarter: 12,900.00 %
|
|
|
